--- title: A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder description: Congenica platform provides variant review and assessment to support conclusive diagnoses for patients with complex and commonly misdiagnosed bleeding disorders. image: https://blog.congenica.com/hubfs/Genetics_People-800x533.jpg --- - [Our Customers and Partners](http://www.congenica.com/our-customers) - [Our Product Portfolio](http://www.congenica.com/congenica-products) - **Inherited Diseases** - [Rare Disease](http://www.congenica.com/congenica-rare-disease) - [Inherited Cancer](http://www.congenica.com/congenica-inherited-cancer) - [Prenatal Health](http://www.congenica.com/congenica-prenatal) - [Carrier Screening](http://www.congenica.com/congenica-carrier-screening) - [Neurodevelopmental Disorders](http://www.congenica.com/congenica-neuro) - **Somatic Oncology** - [Solid Tumours](http://www.congenica.com/congenica-oncology) - **Pathogen** - [Pathogen Surveillance](http://www.congenica.com/congenica-pathogen-surveillance) - [Our Services](http://www.congenica.com/congenica-services) - [Clinical Interpretation Services](http://www.congenica.com/congenica-clinical-interpretation-services) - [Professional Services](http://www.congenica.com/professional-services) - [Customer Support](http://www.congenica.com/customer-support) - [Pharma Services](http://www.congenica.com/pharma-services) - Resources - [Publications](http://www.congenica.com/publications) - [Supporting materials](http://www.congenica.com/resources) - [News](https://blog.congenica.com/) - [Events and webinars](http://www.congenica.com/events-webinars) - [About us](http://www.congenica.com) - [Leadership Team](http://www.congenica.com/leadership) - [Quality](http://www.congenica.com/quality) - [Investors](http://www.congenica.com/investors) - [People and Vacancies](http://www.congenica.com/people) - [Contact us](http://www.congenica.com/contact) Login ##### Please select your location and reference genome: [America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/) [Overview](https://blog.congenica.com) [A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder](https://blog.congenica.com/2019/11/12/a-fast-and-reliable-method-to-reach-a-conclusive-diagnosis-of-myh9-related-disorder) ![A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder](https://blog.congenica.com/hubfs/Genetics_People-800x533.jpg) News # A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder 11/12/2019    |    0 min read **Congenica platform provides variant review and assessment to support conclusive diagnoses for patients with complex and commonly misdiagnosed bleeding disorders in a large multicenter genomic study.** MYH9-related disorder (MYH9-RD) is a complex condition that can have many signs and symptoms, including bleeding problems, hearing loss, kidney disease, and cataracts. The complexity and variability of patients’ clinical presentation can make the diagnosis of MYH9-RD extremely challenging, even by skilled clinicians at specialist centers. As a consequence, a significant number of patients with MYH9-RD are initially misdiagnosed and can receive ineffective and potentially harmful treatments. [A recent study by an international collaboration of researchers](https://onlinelibrary.wiley.com/doi/full/10.1002/humu.23927) has performed the first systematic analysis of MYH9 variants using high throughput sequencing (HTS) analysis in a large cohort of patients and controls enrolled from over 100 centers worldwide. Encouragingly the results demonstrate that an HTS-based strategy is a reliable method to reach a conclusive diagnosis of MYH9-RD in clinical practice. This study collected samples and phenotypic data in more than 3,000 patients with a bleeding or platelet disorder, and sequenced them using HTS. Genetic variants were assessed using the [Congenica](https://www.congenica.com/products-and-services/)[®](https://www.congenica.com/products-and-services/)[clinical decision support platform](https://www.congenica.com/products-and-services/) to visualize the data, assign variant pathogenicity and contribution to phenotype based on the clinical picture, predict consequence in the protein, and check the presence of variants in the Human Gene Mutation Database (HGMD (Stenson, et al 2017)) and their allele frequency in control datasets such as the genome Aggregation Database (gnomAD) (Lek, et al 2016)). Following this analysis, a total of 23 patients were conclusively diagnosed with MYH9-RD after the discovery and characterization of pathogenic and likely pathogenic variants in the *MYH9* gene. Eleven of these patients had a previous clinical suspicion of MYH9-RD, while 12 cases were coded as having an “unclassified platelet disorder” before being analyzed with Congenica. In conclusion, the study was successful in detecting variants causing MYH9-RD, highlighting the heterogeneity of the clinical presentation of the disorder, and expanding the knowledge of the range of *MYH9* genotype-phenotype associations. The application of HTS-based strategies is revealed to be a reliable and fast method to reach a conclusive diagnosis of MYH9-RD allowing clinicians to predict the course of extra-hematological symptoms and may consequently guide the implementation of personalized clinical monitoring and therapies. Find out how Congenica can support you in the diagnosis of complex disorders by booking a personalized demo with a member of the team. See how Congenica can maximize the efficiency of your NGS data analysis and increase your diagnostic yield and confidence. [![Demo Congenica](https://no-cache.hubspot.com/cta/default/6863388/438fdf18-c119-42c4-8d30-73c3d6ddffab.png)](https://cta-redirect.hubspot.com/cta/redirect/6863388/438fdf18-c119-42c4-8d30-73c3d6ddffab) ### References 1. Bury, L. et al. (2019), Next‐generation sequencing for the diagnosis of MYH9‐RD: predicting pathogenic variants. Human Mutation. Accepted Author Manuscript. doi:10.1002/humu.23927 https://onlinelibrary.wiley.com/action/showCitFormats?doi=10.1002%2Fhumu.23927 --- ### Related articles ![SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/hs-fs/hubfs/New%20logos/Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png?width=320&height=192&name=Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png) 9/2/2025 #### [SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/seqone-acquires-congenica-to-create-a-global-leader-in-ai-powered-genomic-medicine) Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries ![Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/hs-fs/hubfs/male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg?width=320&height=192&name=male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg) 11/6/2024 #### [Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/congenica-showcased-in-recently-launched-genomics-spotlight-2024-report) We are thrilled to announce that Congenica is one of the companies showcased in the recently launched Genomics Spotlight 2024 report produced by the UK Department for Business and Trade (DBT). ![Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/hs-fs/hubfs/Onco%20.png?width=320&height=192&name=Onco%20.png) 6/19/2024 #### [Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/congenica-named-best-genomic-data-analysis-software-company-2024-by-ghp) We are thrilled to announce that Congenica has been awarded the title of "Best Genomic Data Analysis Software Company 2024" by Global Health & Pharma Magazine.  ##### Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory. - [Privacy Policy](http://www.congenica.com/privacy-policy) - [Cookie Policy](http://www.congenica.com/cookie-policy) Log in to Congenica ##### Please select your location and reference genome: [America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/) ![CE](https://blog.congenica.com/hs-fs/hubfs/CE.png?width=80&height=80&name=CE.png) ![ISO-27001](https://blog.congenica.com/hs-fs/hubfs/ISO-27001.jpg?width=80&height=80&name=ISO-27001.jpg) ![TR-Testmark_9000030872_EN_2024_CMYK](https://blog.congenica.com/hs-fs/hubfs/2023%20website%20images/TR-Testmark_9000030872_EN_2024_CMYK.png?width=80&height=80&name=TR-Testmark_9000030872_EN_2024_CMYK.png) ![HIPAA Compliant](https://blog.congenica.com/hs-fs/hubfs/HIPAA%20Compliant.png?width=80&height=80&name=HIPAA%20Compliant.png) Copyright © 2026 Congenica Ltd. Company number: 8273616 Registered in England and Wales.